Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.07 EPS

Annexon (NASDAQ:ANNX - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07), Zacks reports.

Annexon Price Performance

ANNX traded up $0.05 during trading hours on Thursday, hitting $1.81. 1,309,427 shares of the stock were exchanged, compared to its average volume of 1,779,431. The stock has a market cap of $198.58 million, a price-to-earnings ratio of -1.72 and a beta of 1.24. The stock has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $3.72. Annexon has a 12 month low of $1.29 and a 12 month high of $7.85.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Needham & Company LLC reduced their price target on shares of Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday. HC Wainwright cut their price objective on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.